Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mebix's EDC Receives CDISC Certification
August 30, 2010
- Industry-Funded Trials More Likely to Publish Favorable Results: US Study
August 30, 2010
- JMA Expresses Concern about Commercial Use of Social Security Numbering System
August 30, 2010
- DSP Screens Candidates for Lurasidone's Successors
August 30, 2010
- Korosho to Help Drug Industry Become Japan's Leading Industry: Mr Asonuma
August 30, 2010
- AnGes MG to Undertake Joint Research on siRNA with alphaGEN
August 30, 2010
- Korosho to Create 10 Million-Person DB on ADR: Mr Nagatsuma
August 30, 2010
- Nesina Jumps to No. 1 Place in GP Market: Rep Track Survey
August 30, 2010
- Korosho to Allow Reimbursement of Drugs Applied Based on Data from Public Domain
August 30, 2010
- Toxicity Study Completed for LTT Bio-Pharma's Inhalant PC-SOD
August 30, 2010
- Non-specialists Should Rely on New Anti-Epileptic Drugs: Prof. Nakasato
August 30, 2010
- Wholesalers' Gross Profit Rate below 7% for the First Time
August 30, 2010
- Korosho Invites Applicants for Development of Diaminopyridine
August 30, 2010
- Anti-IL-6 Receptor Antibody Effective for IBD: NIBIO, Osaka Univ.
August 30, 2010
- Rohto: Sales Down due to Slump of Pollinosis, Metabolic Syndrome-Related Products
August 30, 2010
- Teijin: Maintains Top Market Share for Osteoporosis Drugs
August 30, 2010
- Canakinumab, KW-0761 Designated as Orphan Drugs
August 30, 2010
- Vectibix Fails to Prolong OS in Head and Neck Cancer
August 30, 2010
- Pfizer Applies for Its 1st Generics Aiming at Listing in 2011
August 30, 2010
- Meiji Seika: Sales Up 16.6% Driven by New Drugs
August 30, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…